连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的临床疗效研究

Clinical Study on Treatment of COVID-19 in Convalescent Period Treated with Lianhua Qingwen Capsule Combined with Interferon α-2b

摘要: 目的：探讨连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的临床疗效研究。方法：选取我院收治的70例新冠肺炎康复期病人，随机分为对照组和观察组，每组35例。对照组采用阿比多尔+干扰素α-2b治疗，观察组采用连花清瘟颗粒联合干扰素α-2b治疗，对比两组患者的临床疗效、CT检查结果以及治疗前后的临床症状得分。结果：对照组患者的总有效率为68.57%，出院率为11.42%，CT疗效的总有效率率为62.86%，观察组的中患者的总有效率94.29%，出院率为42.86%，CT疗效的总有效率为85.71%，观察组患者的临床疗效的总有效率、CT疗效的总有效率以及出院率明显高于对照组(P < 0.05)。治疗前，两组患者的临床症状得分比较无显著差异(P > 0.05)。治疗后，两组患者的临床症状得分明显低于治疗前，观察组的临床症状得分明显低于对照组(P < 0.05)。结论：连花清瘟胶囊联合干扰素α-2b治疗新冠肺炎康复期病人的疗效显著，可有效降低临床症状，提高出院率。

Abstract: Objective: To analyze the clinical effect of COVID-19 in convalescent period treated by Lianhua Qingwen capsule combined with Interferon α-2b. Methods: 70 patients with COVID-19 in convalescent period were randomly divided into control group and study group, 35 cases in each group. The control group was treated with arbidol combined with Interferon α-2b, and the study group was treated with Lianhua Qingwen capsule combined with Interferon α-2b. The clinical efficacy, CT findings and clinical symptom scores before and after treatment were compared between the two groups. Results: The total effective rate of the control group was 68.57%, the discharge rate was 11.42%, the total effective rate of CT effect was 62.86%, the total effective rate of the observation group was 94.29%, the discharge rate was 42.86%, and the total effective rate of CT effect was 85.71%. The total effective rate of clinical effect, CT effect and discharge rate in the observation group were significantly higher than those in the control group (P < 0.05). Before treatment, there was no significant difference in clinical symptom scores between the two groups (P > 0.05). After treatment, the clinical symptom scores of the two groups were significantly lower than that before treatment, and the clinical symptom scores of the observation group were significantly lower than that of the control group (P < 0.05). Conclusion: The therapeutic effect of Lianhua Qingwen capsule combined with Interferon α-2b on COVID-19 in convalescent period is significant, which can effectively reduce the clinical symptoms and improve the discharge rate.